Evicenter
P&T meetings

AXPAXLI

Neovascular age-related macular degeneration

Also known as axitinib intravitreal implant, OTX-TKI
Manufacturer
Ocular Therapeutix
309 sources

Section 6 of 6

References

309 sources

  1. 4DMT second-quarter 2026 results announcement (2026) (opens in a new tab)
  2. Abu Al-Burak et al. (2026) (opens in a new tab)
  3. Acharya et al. (2025) (opens in a new tab)
  4. Age-Related Eye Disease Study 2 Research Group (2013) (opens in a new tab)
  5. Age-Related Eye Disease Study 2 Research Group (2018) (opens in a new tab)
  6. Age-Related Eye Disease Study Research Group (2001) (opens in a new tab)
  7. Agrón et al. (2024) (opens in a new tab)
  8. Al-Khersan et al. (2022) (opens in a new tab)
  9. Almony et al. (2021) (opens in a new tab)
  10. Ambresin et al. (2025) (opens in a new tab)
  11. American Academy of Ophthalmology (opens in a new tab)
  12. American Academy of Ophthalmology IRIS63 measure specification (opens in a new tab)
  13. American Society of Retina Specialists Preferences and Trends Survey (2026) (opens in a new tab)
  14. Amin and Kaiser (2026) (opens in a new tab)
  15. Amoaku et al. (2015) (opens in a new tab)
  16. Anastasopoulos et al. (2006) (opens in a new tab)
  17. AREDS2-HOME Study Research Group (2014) (opens in a new tab)
  18. AREDS2-HOME Study Research Group (2014) (opens in a new tab)
  19. Augustin et al. (2007) (opens in a new tab)
  20. Avery (2023) (opens in a new tab)
  21. Bailey et al. (2019) (opens in a new tab)
  22. Bakri et al. (2024) (opens in a new tab)
  23. Baljoon et al. (2026) (opens in a new tab)
  24. Banister et al. (2022) (opens in a new tab)
  25. Barakat et al. (2025) (opens in a new tab)
  26. Berkowitz and Patel (2021) (opens in a new tab)
  27. Berkowitz et al. (2019) (opens in a new tab)
  28. Blizzard et al. (2024) (opens in a new tab)
  29. Bloch et al. (2012) (opens in a new tab)
  30. Boyle et al. (2018) (opens in a new tab)
  31. Bressler et al. (2010) (opens in a new tab)
  32. Bressler et al. (2023) (opens in a new tab)
  33. Brody et al. (2001) (opens in a new tab)
  34. Brown et al. (2000) (opens in a new tab)
  35. Brown et al. (2002) (opens in a new tab)
  36. Brown et al. (2005) (opens in a new tab)
  37. Brown et al. (2006) (opens in a new tab)
  38. Brown et al. (2015) (opens in a new tab)
  39. Brown et al. (2020) (opens in a new tab)
  40. Brown et al. (2021) (opens in a new tab)
  41. Brown et al. (2024) (opens in a new tab)
  42. Brown et al. (2025) (opens in a new tab)
  43. Bryan et al. (2025) (opens in a new tab)
  44. Butler et al. (2025) (opens in a new tab)
  45. CADTH (2022) (opens in a new tab)
  46. CADTH reimbursement recommendation (2022) (opens in a new tab)
  47. Campochiaro et al. (2025) (opens in a new tab)
  48. Castillo et al. (2014) (opens in a new tab)
  49. CATT Research Group (2011) (opens in a new tab)
  50. CATT Research Group (2012) (opens in a new tab)
  51. CDA-AMC (2024) (opens in a new tab)
  52. CDA-AMC reimbursement recommendation (2024) (opens in a new tab)
  53. Centers for Medicare & Medicaid Services (2018) (opens in a new tab)
  54. Chakravarthy et al. (2010) (opens in a new tab)
  55. Chakravarthy et al. (2013) (opens in a new tab)
  56. Chandra et al. (2023) (opens in a new tab)
  57. Cheung et al. (2021) (opens in a new tab)
  58. Chew et al. (2022) (opens in a new tab)
  59. Choi et al. (2023) (opens in a new tab)
  60. Ciulla et al. (2020) (opens in a new tab)
  61. Clemons et al. (2004) (opens in a new tab)
  62. ClinicalTrials.gov NCT03630315 (opens in a new tab)
  63. ClinicalTrials.gov NCT04989699 (opens in a new tab)
  64. ClinicalTrials.gov NCT06223958 (opens in a new tab)
  65. ClinicalTrials.gov NCT06495918 (opens in a new tab)
  66. ClinicalTrials.gov NCT07516132 (opens in a new tab)
  67. Comparison of Age-related Macular Degeneration Treatments Trials Research Group (2016) (opens in a new tab)
  68. Congdon et al. (2004) (opens in a new tab)
  69. Cornish et al. (2021) (opens in a new tab)
  70. Cruess et al. (2008) (opens in a new tab)
  71. DailyMed BEOVU prescribing information (2024) (opens in a new tab)
  72. DailyMed BYOOVIZ prescribing information (2025) (opens in a new tab)
  73. DailyMed CIMERLI prescribing information (2024) (opens in a new tab)
  74. DailyMed EYLEA HD prescribing information (2026) (opens in a new tab)
  75. DailyMed EYLEA prescribing information (2024) (opens in a new tab)
  76. DailyMed INLYTA prescribing information (2024) (opens in a new tab)
  77. DailyMed LUCENTIS prescribing information (2024) (opens in a new tab)
  78. DailyMed PAVBLU prescribing information (2026) (opens in a new tab)
  79. DailyMed SUSVIMO prescribing information (2025) (opens in a new tab)
  80. DailyMed VABYSMO prescribing information (2026) (opens in a new tab)
  81. DailyMed VISUDYNE prescribing information (2021) (opens in a new tab)
  82. Daniel et al. (2014) (opens in a new tab)
  83. Daniel et al. (2018) (opens in a new tab)
  84. Danzig et al. (2025) (opens in a new tab)
  85. Dawson et al. (2014) (opens in a new tab)
  86. Day et al. (2011) (opens in a new tab)
  87. Delcourt et al. (2026) (opens in a new tab)
  88. Dhoot et al. (2022) (opens in a new tab)
  89. Dhoot et al. (2025) (opens in a new tab)
  90. Dhoot et al. (2026) (opens in a new tab)
  91. Dickson and James (2023) (opens in a new tab)
  92. Do et al. (2012) (opens in a new tab)
  93. Dugel et al. (2020) (opens in a new tab)
  94. Dugel et al. (2021) (opens in a new tab)
  95. Eichenbaum et al. (2024) (opens in a new tab)
  96. Eichenbaum et al. (2025) (opens in a new tab)
  97. El Alili et al. (2026) (opens in a new tab)
  98. Emami-Naeini et al. (2024) (opens in a new tab)
  99. Emerson et al. (2020) (opens in a new tab)
  100. Espallargues et al. (2005) (opens in a new tab)
  101. EyePoint LUGANO topline announcement (2026) (opens in a new tab)
  102. Faes et al. (2019) (opens in a new tab)
  103. FDA Biosimilar Product Information (2026) (opens in a new tab)
  104. Ferris et al. (2005) (opens in a new tab)
  105. Ferris et al. (2013) (opens in a new tab)
  106. Finger et al. (2020) (opens in a new tab)
  107. Finn et al. (2023) (opens in a new tab)
  108. Flaxel et al. (2020) (opens in a new tab)
  109. Fleckenstein et al. (2021) (opens in a new tab)
  110. Fleckenstein et al. (2024) (opens in a new tab)
  111. Franco and Wubben (2026a) (opens in a new tab)
  112. Franco et al. (2026b) (opens in a new tab)
  113. Frank et al. (1996) (opens in a new tab)
  114. Freund et al. (2008) (opens in a new tab)
  115. Friedman et al. (2004) (opens in a new tab)
  116. Fritsche et al. (2016) (opens in a new tab)
  117. Gale et al. (2023) (opens in a new tab)
  118. Gale et al. (2026) (opens in a new tab)
  119. Garmo et al. (2024) (opens in a new tab)
  120. GBD 2019 Blindness and Vision Impairment Collaborators (2021) (opens in a new tab)
  121. GBD 2021 Global AMD Collaborators (2025) (opens in a new tab)
  122. Genentech (2024) (opens in a new tab)
  123. Genentech (2025) (opens in a new tab)
  124. Gibson (2025) (opens in a new tab)
  125. Giddabasappa et al. (2016) (opens in a new tab)
  126. Gillies et al. (2015) (opens in a new tab)
  127. Gismero Moreno et al. (2025) (opens in a new tab)
  128. Gohil et al. (2015) (opens in a new tab)
  129. Gragoudas et al. (2004) (opens in a new tab)
  130. Grunwald et al. (2017) (opens in a new tab)
  131. Hanemoto et al. (2017) (opens in a new tab)
  132. Heier (2026) (opens in a new tab)
  133. Heier et al. (2012) (opens in a new tab)
  134. Heier et al. (2022) (opens in a new tab)
  135. Hernandez et al. (2018) (opens in a new tab)
  136. Hernandez et al. (2022) (opens in a new tab)
  137. Holekamp et al. (2014) (opens in a new tab)
  138. Holekamp et al. (2022) (opens in a new tab)
  139. Holekamp et al. (2024) (opens in a new tab)
  140. Holz et al. (2015) (opens in a new tab)
  141. Holz et al. (2016) (opens in a new tab)
  142. Holz et al. (2020) (opens in a new tab)
  143. Holz et al. (2022) (opens in a new tab)
  144. Hutton et al. (2014) (opens in a new tab)
  145. Hwang et al. (2023) (opens in a new tab)
  146. Javitt et al. (2003) (opens in a new tab)
  147. Jung et al. (2014) (opens in a new tab)
  148. Kahn et al. (2022) (opens in a new tab)
  149. Kertes et al. (2020) (opens in a new tab)
  150. Khanani et al. (2020) (opens in a new tab)
  151. Khanani et al. (2022) (opens in a new tab)
  152. Khanani et al. (2023) (opens in a new tab)
  153. Khanani et al. (2024) (opens in a new tab)
  154. Khurana et al. (2023) (opens in a new tab)
  155. Kiss et al. (2014) (opens in a new tab)
  156. Kiss et al. (2020a) (opens in a new tab)
  157. Kiss et al. (2020b) (opens in a new tab)
  158. Klein et al. (2007) (opens in a new tab)
  159. Klein et al. (2011) (opens in a new tab)
  160. Kuznik et al. (2025) (opens in a new tab)
  161. Kvanta et al. (1996) (opens in a new tab)
  162. Lanzetta et al. (2024) (opens in a new tab)
  163. Lazzara et al. (2024) (opens in a new tab)
  164. Li et al. (2020) (opens in a new tab)
  165. Liu et al. (2022) (opens in a new tab)
  166. Loewenstein et al. (2025) (opens in a new tab)
  167. Løkken et al. (2026) (opens in a new tab)
  168. Lotery et al. (2007) (opens in a new tab)
  169. Macula Society Annual Meeting (2026) (opens in a new tab)
  170. Macular Photocoagulation Study Group (1991) (opens in a new tab)
  171. Maesa et al. (2022) (opens in a new tab)
  172. Maguire et al. (2013) (opens in a new tab)
  173. Managed Healthcare Executive (2026) (opens in a new tab)
  174. McGuinness et al. (2017) (opens in a new tab)
  175. McGuire et al. (2026) (opens in a new tab)
  176. MedPAC Data Book (2025) (opens in a new tab)
  177. MedPAC Data Book (2026) (opens in a new tab)
  178. Mehta et al. (2018) (opens in a new tab)
  179. Mehta et al. (2020) (opens in a new tab)
  180. Mitchell et al. (2018) (opens in a new tab)
  181. Mitchell et al. (2021) (opens in a new tab)
  182. Mohan et al. (2026) (opens in a new tab)
  183. Monés et al. (2020) (opens in a new tab)
  184. Monés et al. (2021) (opens in a new tab)
  185. Moshfeghi et al. (2021) (opens in a new tab)
  186. Moshfeghi et al. (2022a) (opens in a new tab)
  187. Moshfeghi et al. (2022b) (opens in a new tab)
  188. Moshfeghi et al. (2023a) (opens in a new tab)
  189. Moshfeghi et al. (2023b) (opens in a new tab)
  190. Moshfeghi et al. (2023c) (opens in a new tab)
  191. Mowatt et al. (2014) (opens in a new tab)
  192. Nam and Yun (2025) (opens in a new tab)
  193. Niazi et al. (2020) (opens in a new tab)
  194. NICE (2018) (opens in a new tab)
  195. NICE (2022) (opens in a new tab)
  196. NICE (2022) (opens in a new tab)
  197. NICE resource impact report (2022) (opens in a new tab)
  198. Notal Vision (2024) (opens in a new tab)
  199. Obeid et al. (2018) (opens in a new tab)
  200. Ocular Therapeutix 12-month U.S. phase 1 results announcement (2023) (opens in a new tab)
  201. Ocular Therapeutix additional Week 52 data announcement (2026) (opens in a new tab)
  202. Ocular Therapeutix first subjects screened announcement (2024) (opens in a new tab)
  203. Ocular Therapeutix Form 10-K (2026) (opens in a new tab)
  204. Ocular Therapeutix Form 10-Q (2026) (opens in a new tab)
  205. Ocular Therapeutix Investor Day announcement (2024) (opens in a new tab)
  206. Ocular Therapeutix Investor Day announcement (2026) (opens in a new tab)
  207. Ocular Therapeutix Investor Day presentation (2026) (opens in a new tab)
  208. Ocular Therapeutix NDA acceleration announcement (2025) (opens in a new tab)
  209. Ocular Therapeutix pre-NDA meeting announcement (2026) (opens in a new tab)
  210. Ocular Therapeutix second-quarter 2026 results announcement (2026) (opens in a new tab)
  211. Ocular Therapeutix SOL-1 randomization announcement (2024) (opens in a new tab)
  212. Ocular Therapeutix SOL-1 topline results announcement (2026) (opens in a new tab)
  213. Ocular Therapeutix SOL-R enrollment closing announcement (2025) (opens in a new tab)
  214. Ocular Therapeutix SOL-R enrollment progress announcement (2025) (opens in a new tab)
  215. Ocular Therapeutix SOL-R FDA feedback announcement (2024) (opens in a new tab)
  216. Ocular Therapeutix SOL-R target randomization announcement (2025) (opens in a new tab)
  217. Ocular Therapeutix SOL-X first patient announcement (2026) (opens in a new tab)
  218. Ocular Therapeutix SPA agreement announcement (2023) (opens in a new tab)
  219. Ocular Therapeutix SPA amendment announcement (2024) (opens in a new tab)
  220. Ocular Therapeutix treatment burden analysis presentation (2026) (opens in a new tab)
  221. Ohji et al. (2020) (opens in a new tab)
  222. Okada et al. (2021) (opens in a new tab)
  223. Patel (2018) (opens in a new tab)
  224. Patel and Sternberg (2022b) (opens in a new tab)
  225. Patel et al. (2012) (opens in a new tab)
  226. Patel et al. (2022a) (opens in a new tab)
  227. Patel et al. (2024) (opens in a new tab)
  228. Patel et al. (2025) (opens in a new tab)
  229. Patil et al. (2024) (opens in a new tab)
  230. Paudel et al. (2024) (opens in a new tab)
  231. Pearson et al. (2013) (opens in a new tab)
  232. Peto et al. (2022) (opens in a new tab)
  233. Pitsillidou et al. (2026) (opens in a new tab)
  234. Prenner et al. (2015) (opens in a new tab)
  235. Quist et al. (2025) (opens in a new tab)
  236. Rao et al. (2018) (opens in a new tab)
  237. REGENXBIO second-quarter 2026 results announcement (2026) (opens in a new tab)
  238. Rein et al. (2022a) (opens in a new tab)
  239. Rein et al. (2022b) (opens in a new tab)
  240. Reitan et al. (2023) (opens in a new tab)
  241. Review of Ophthalmology (2022) (opens in a new tab)
  242. Robinson et al. (2025) (opens in a new tab)
  243. Rofagha et al. (2013) (opens in a new tab)
  244. Rosenfeld et al. (2006) (opens in a new tab)
  245. Rosenfeld et al. (2018) (opens in a new tab)
  246. Rovner et al. (2002) (opens in a new tab)
  247. Rovner et al. (2007) (opens in a new tab)
  248. Rovner et al. (2014) (opens in a new tab)
  249. Rowe et al. (2025) (opens in a new tab)
  250. Rudnicka et al. (2015) (opens in a new tab)
  251. Schlottmann (2025) (opens in a new tab)
  252. Schlottmann et al. (2026) (opens in a new tab)
  253. Schmidt-Erfurth et al. (2014) (opens in a new tab)
  254. Schmier et al. (2006) (opens in a new tab)
  255. Schuster et al. (2023) (opens in a new tab)
  256. Senra et al. (2016) (opens in a new tab)
  257. Senra et al. (2017) (opens in a new tab)
  258. Sheth et al. (2026) (opens in a new tab)
  259. Shirian et al. (2025) (opens in a new tab)
  260. Siddiqui et al. (2022) (opens in a new tab)
  261. Siedlecki et al. (2017) (opens in a new tab)
  262. Siedlecki et al. (2018) (opens in a new tab)
  263. Singh and Sørensen (2012) (opens in a new tab)
  264. Sivaprasad et al. (2024) (opens in a new tab)
  265. Sobolewska et al. (2021) (opens in a new tab)
  266. Solomon et al. (2019) (opens in a new tab)
  267. Sood et al. (2022) (opens in a new tab)
  268. Soubrane et al. (2007) (opens in a new tab)
  269. Spaide et al. (2020) (opens in a new tab)
  270. Spooner et al. (2018) (opens in a new tab)
  271. Spooner et al. (2025) (opens in a new tab)
  272. Spooner et al. (2026) (opens in a new tab)
  273. Stein et al. (2014) (opens in a new tab)
  274. Stelmack et al. (2008) (opens in a new tab)
  275. Suñer et al. (2009) (opens in a new tab)
  276. TAP Study Group (1999) (opens in a new tab)
  277. TipRanks (2026) (opens in a new tab)
  278. Tran et al. (2024) (opens in a new tab)
  279. Tsang et al. (2024) (opens in a new tab)
  280. Tufail et al. (2026) (opens in a new tab)
  281. UnitedHealthcare Medicare Part B Step Therapy Programs (2026) (opens in a new tab)
  282. Varano et al. (2015) (opens in a new tab)
  283. Vemulakonda et al. (2025) (opens in a new tab)
  284. Vemulakonda et al. (2025) (opens in a new tab)
  285. Vinge and Bro (2024) (opens in a new tab)
  286. Viola et al. (2024) (opens in a new tab)
  287. Violato et al. (2016) (opens in a new tab)
  288. Vision Loss Expert Group of the Global Burden of Disease Study (2024) (opens in a new tab)
  289. Vit-Buckle Society Annual Meeting (2026) (opens in a new tab)
  290. Vitale et al. (2020) (opens in a new tab)
  291. Vukicevic et al. (2016) (opens in a new tab)
  292. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
  293. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
  294. Wibbelsman et al. (2019) (opens in a new tab)
  295. Willmington et al. (2025) (opens in a new tab)
  296. Windsor et al. (2018) (opens in a new tab)
  297. Wong et al. (2008) (opens in a new tab)
  298. Wong et al. (2014) (opens in a new tab)
  299. Wong et al. (2021a) (opens in a new tab)
  300. Wong et al. (2021b) (opens in a new tab)
  301. Woo et al. (2021) (opens in a new tab)
  302. Wood et al. (2011) (opens in a new tab)
  303. Wykoff et al. (2017) (opens in a new tab)
  304. Wykoff et al. (2018) (opens in a new tab)
  305. Wykoff et al. (2024a) (opens in a new tab)
  306. Wykoff et al. (2024b) (opens in a new tab)
  307. Xin et al. (2018) (opens in a new tab)
  308. Zarranz-Ventura et al. (2014) (opens in a new tab)
  309. Zhang et al. (2023) (opens in a new tab)